Bausch+Lomb Results Presentation Deck
Reconciliation of Reported Revenue to Constant Currency Revenue ¹ and
Constant Currency Revenue Growth¹ ($M)
Bausch + Lomb
Vision Care²
Surgical
Ophthalmic Pharmaceuticals²
Total Bausch + Lomb
BAUSCH + LOMB
2.
3
$
$
Calculation of Constant Currency Revenue for the Three Months Ended
March 31, 2023
March 31, 2022
Revenue as
Reported
587
183
161
931
Changes in
Exchange Rates³
S
$
20
6
5
31
Constant
Currency
Revenue (Non-
GAAP)¹
$
$
$
607
189
166
962 $
Revenue as
Reported
560
174
155
889
$
$
Change in
Reported Revenue
Amount
27
9
6
42
Pct.
Change in
Constant Currency Revenue¹
5% $
5%
4%
5%
$
Amount
47
15
11
73
Pct.
8%
9%
7%
8%
This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in
the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the
groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the
monthly average currency exchange rates during the comparable prior period.
28View entire presentation